Quel est le prix pour Novartis AG (NVS)

Le prix pour Novartis AG (NVS) est $148.18

Quelle est la capitalisation boursière pour Novartis AG (NVS)

La capitalisation boursière pour Novartis AG (NVS) est $286.44B

Revenus de Novartis AG (NVS)

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Année	Revenus	Changez
Pas assez de données pour les dates fournies.

Année

Revenus

Changez

Pas assez de données pour les dates fournies.

Entreprise	Revenus	Différence de revenus	Pays
Eli Lilly LLY.US	$65.18B	-	US
AstraZeneca PLC AZN.US	$58.74B	-	GB
Johnson & Johnson JNJ.US	$94.19B	-	US
AbbVie Inc. ABBV.US	$61.16B	-	US
Merck & Co., Inc. MRK.US	$65.01B	-	US

Entreprise

Revenus

Différence de revenus

Pays